Full Title
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid TumorsPurpose
Researchers want to find the best dose of ORM-5029 for people with advanced breast cancer that makes the HER2 protein. ORM-5029 may be useful in people who cannot receive other HER2-targeted treatments or whose cancer keeps growing with these drugs. ORM-5029 works in a different way than those drugs. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have HER2-positive advanced breast cancer that cannot be successfully treated with other HER2-targeted drugs, or has grown despite treatment with those drugs.
- Have completed any prior anti-cancer medications and radiation therapy at least 2 weeks before getting ORM-5029.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Joshua Drago’s office at 646-888-6971.
Protocol
24-218
Phase
Phase I (phase 1)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT05511844